[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2018, Vol. 40 ›› Issue (2): 87-94.doi: 10.16288/j.yczz.17-255

• Orginal Article •     Next Articles

Fragile X mental retardation protein participates in non-coding RNA pathways

Enhui Li1(),Xin Zhao1,Ce Zhang1,Wei Liu2()   

  1. 1. Department of Physiology, Shanxi Medical University, Taiyuan 030001, China
    2. Department of Examination, Fenyang College of Shanxi Medical University, Fenyang 032200, China
  • Received:2017-11-07 Revised:2018-01-05 Online:2018-02-20 Published:2018-01-11
  • Supported by:
    the National Natural Science Foundation of China(31501175);Key Developing Program for Science and Technique of Shanxi Medical University Fenyang College(2018C02)

Abstract:

Fragile X syndrome is one of the most common forms of inherited intellectual disability. It is caused by mutations of the Fragile X mental retardation 1(FMR1) gene, resulting in either the loss or abnormal expression of the Fragile X mental retardation protein (FMRP). Recent research showed that FMRP participates in non-coding RNA pathways and plays various important roles in physiology, thereby extending our knowledge of the pathogenesis of the Fragile X syndrome. Initial studies showed that the Drosophila FMRP participates in siRNA and miRNA pathways by interacting with Dicer, Ago1 and Ago2, involved in neural activity and the fate determination of the germline stem cells. Subsequent studies showed that the Drosophila FMRP participates in piRNA pathway by interacting with Aub, Ago1 and Piwi in the maintenance of normal chromatin structures and genomic stability. More recent studies showed that FMRP is associated with lncRNA pathway, suggesting a potential role for the involvement in the clinical manifestations. In this review, we summarize the novel findings and explore the relationship between FMRP and non-coding RNA pathways, particularly the piRNA pathway, thereby providing critical insights on the molecular pathogenesis of Fragile X syndrome, and potential translational applications in clinical management of the disease.

Key words: FMRP, non-coding RNA pathway, piRNA, genome integrity, Drosophila